You are here

P&T May 2016


Editor’s Memo

Although the death rate from cancer has fallen in recent years, progress against these diseases is uneven. This issue focuses on research efforts to find treatments.

Despite Funding Questions, the Progress Appears Promising

The Obama administration has announced a drive to cure cancer, although the mission has been under way for decades. How are researchers doing, and what is in store?


Medication Errors

We must ensure safer use of oral chemotherapy

Prescription: Washington

CMS stands pat on exchange formulary standards

Approvals, new indications, regulatory activities, and more

Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A

Meeting Highlights

Key sessions at HemOnc Today covered systemic and locoregional use of immunotherapies.

Meeting Highlights

At the cardiology meeting, preventive strategies took center stage.